U.S. markets closed

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
330.53-7.06 (-2.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close337.59
Open334.55
Bid275.00 x 800
Ask330.72 x 900
Day's Range329.82 - 339.08
52 Week Range159.01 - 387.40
Volume269,909
Avg. Volume320,596
Market Cap14.95B
Beta (5Y Monthly)1.31
PE Ratio (TTM)75.34
EPS (TTM)4.39
Earnings DateApr 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est378.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
40% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is Abiomed, Inc.'s(NASDAQ:ABMD) Recent Stock Performance Tethered To Its Strong Fundamentals?
    Simply Wall St.

    Is Abiomed, Inc.'s(NASDAQ:ABMD) Recent Stock Performance Tethered To Its Strong Fundamentals?

    Abiomed's (NASDAQ:ABMD) stock is up by a considerable 9.4% over the past month. Given the company's impressive...

  • First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
    Business Wire

    First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella

    Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber, chief of cardiology at Ascension St. John Macomb-Oakland Hospital and Dr. Amir Kaki, interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital.

  • 3 Overlooked Healthcare Stocks to Buy Right Now
    Motley Fool

    3 Overlooked Healthcare Stocks to Buy Right Now

    Here, I'll talk about three overlooked healthcare stocks to buy now for big reward potential well into the future. Intuitive Surgical (NASDAQ: ISRG) has slipped about 6% since the start of the year. This leader in robotic surgery holds more than 80% of the global market, a report from Informa Pharma Intelligence shows.